Table N° 2. Baseline demographic, clinical, and laboratory characteristics of patients and controls.
| Variable | Control group | Ruxolitinib group |
|---|---|---|
| N | 51 | 51 |
| Age, years (median, range) | 59 | 57 |
| (28-80) | (28-79) | |
| Male | 35 (69%) | 37 (73%) |
| COVID-19 onset atypical symptoms (chest pain) | 0% | 1.9% |
| Time from initial symptoms to diagnosis, days (median, range) | 4 | 2 |
| (0-11) | (0-10) | |
| Time from initial symptoms to hospitalization, days (median, range) | 5 | 5 |
| (0-12) | (0-11) | |
| Clinical characteristics | ||
| Overweight/obesity | 18 | 23 |
| (35.3%) | (45.1%) | |
| Hypertension (*) | 12 | 24 |
| (23.5%) | (47%) | |
| Chronic pulmonary disease | 3 | 9 |
| (5.9%) | (17.6%) | |
| Prostatic hyperplasia | 3 | 0 |
| (5.9%) | 0% | |
| Chronic renal failure | 2 | 0 |
| (3.9%) | 0% | |
| Diabetes mellitus | 13 | 17 |
| (25.5%) | (33.3%) | |
| Arrhythmia | 0 | 1 |
| 0% | (1.9%) | |
| Basocellular skin cancer | 0 | 1 |
| 0% | (1.9%) | |
| Lung cancer | 1 | 0 |
| (1.9%) | 0% | |
| Congenital brachial paralysis | 0 | 1 |
| 0% | (1.9%) | |
| Coronary heart disease | 3 | 2 |
| (5.9%) | (3.9%) | |
| Glaucoma | 0 | 1 |
| 0% | (1.9%) | |
| Hypothyroidism | 3 | 7 |
| (5.9%) | (13.7%) | |
| Renal cancer | 0 | 1 |
| 0% | (1.9%) | |
| Epilepsy | 1 | 0 |
| (1.9%) | 0% | |
| Herpes genital | 1 | 0 |
| (1.9%) | 0% | |
| Liver cirrhosis | 1 | 0 |
| (1.9%) | 0% | |
| Basal hematological parameters | ||
| Hemoglobin, g/dl (median, range) | 13.9 | 14.35 |
| (7.9-17.7) | (10.4-16.7) | |
| White blood cells, /µl (median, range) | 6290 | 9050 |
| (140-17500) | (3910-20440) | |
| Lymphocytes, /µl (median, range) | 1025 | 928.5 |
| (162-2150) | (357-2182) | |
| Platelets, 103 cells/µl (median, range) | 216 | 247 |
| (56-646) | (121-481.5) | |
All data are n (%), except when specified
No statistic differences was shown between groups, except for (*) p < 0.05 (chi squared test)